These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24731479)

  • 1. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
    Wu K; Yang Q; Liu Y; Wu A; Yang Z
    World J Surg Oncol; 2014 Apr; 12():95. PubMed ID: 24731479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
    BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
    Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
    Chen XS; Yuan Y; Garfield DH; Wu JY; Huang O; Shen KW
    PLoS One; 2014; 9(9):e108405. PubMed ID: 25247558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
    Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
    Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer.
    Zhang G; Xie W; Liu Z; Lin C; Piao Y; Xu L; Guo F; Xie X
    Tumori; 2014; 100(2):136-42. PubMed ID: 24852856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
    Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
    JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
    Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
    Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
    Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
    Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
    J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
    Matsuda N; Kida K; Ohde S; Suzuki K; Yamauchi H; Nakamura S; Tsunoda H
    Breast Cancer; 2018 Jan; 25(1):43-49. PubMed ID: 28536943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
    JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
    Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.